Skip to main content

Market Overview

Ayala's Stock Surges After Ladenburg Initiates Coverage With Price Target Of $29

Ayala's Stock Surges After Ladenburg Initiates Coverage With Price Target Of $29
  • Ayala Pharmaceuticals Inc (NASDAQ: AYLAinitiated with Buy with a $29 (around 120% upside) at Ladenburg Thalmann analyst price target. 
  • The analyst says the company has the most diversified gamma-secretase inhibitor play in the public markets. 
  • Demir sees near-to-medium term value play considering Ayala's "wide clinical pipeline that offers plenty of interesting /compelling optionality."
  • In April, the first patient was dosed in Phase 1 AL102 Combination Trial with Novartis' Anti-BCMA Agent for multiple myeloma.
  • Ayala expects an initial interim data read-out from part A of desmoid tumor Phase 2/3 pivotal trial study and dose selection by mid-2022.
  • Cash and cash equivalents of $56 million are sufficient to provide a cash runway into 2023.
  • Price Action: AYLA shares are up 17.3% at $12.43 during the market session on the last check Tuesday.

Latest Ratings for AYLA

Aug 2021OppenheimerMaintainsOutperform
Jul 2021Ladenburg ThalmannInitiates Coverage OnBuy
Dec 2020Roth CapitalInitiates Coverage OnBuy

View More Analyst Ratings for AYLA
View the Latest Analyst Ratings


Related Articles (AYLA)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech News Health Care Price Target Initiation Analyst Ratings General

Latest Ratings

CMCSAExane BNP ParibasInitiates Coverage On72.0
CHTRExane BNP ParibasInitiates Coverage On956.0
CRBMO CapitalUpgrades3.3
SEELRoth CapitalUpgrades8.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at